Figure 5From: Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study Kaplan-Meier plot for overall survival (OS). The median OS was 49 months in the TACE-BEV arm (solid line) and 61 months in the TACE-O arm (dashed line), with a p-value of 0.21Back to article page